Evidence for improvements to risk stratification in high-risk gastrointestinal stromal tumor patients

References

• Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence clinical course, and prognostication in the pre-imatinib mesylate era-a population based study in western Sweden. Cancer. 2005;103:821–829.
   PubMed Web of Science ®Google Scholar
• Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol. 2000;15:1293–1301.
   PubMed Web of Science ®Google Scholar
• Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411–1419.
   PubMed Web of Science ®Google Scholar
• McWhinney SR, Pasini B, Stratakis CA; International Carney Triad and Carney-Stratakis Syndrome Consortium. Familial gastrointestinal stromal tumors and germ-line mutations. N Engl J Med. 2007;357(10):1054–1056.
   PubMed Web of Science ®Google Scholar
• Pasini B, Mcwhinney SR, Bei T, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet. 2008;16(1):79–88.
   Web of Science ®Google Scholar
• Gasparotto D, Rossi S, Polano M, et al. Quadruple-negative GIST is a sentinel for unrecognized neurofibromatosis type 1 syndrome. Clin Cancer Res. 2017;23:273–282.
   PubMed Web of Science ®Google Scholar
• Rossi S, Gasparotto D, Cacciatore M, et al. Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs. Mod Pathol. 2018;31(1):160–168.
   Web of Science ®Google Scholar
• Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Gen Chrom Cancer. 2008;47:853–859.
   PubMed Web of Science ®Google Scholar
• Brenca M, Rossi S, Polano M, et al. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. J Pathol. 2016;238(4):543–549.
   PubMed Web of Science ®Google Scholar
• Shi E, Chmielecki J, Tang CM, et al. FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors. J Transl Med. 2016;14(1):339.
   PubMedGoogle Scholar
• Florou V, Wilky BA, Trent JC. Latest advances in adult gastrointestinal stromal tumors. Future Oncol. 2017;13(24):2183–2193.
   Web of Science ®Google Scholar
• Wong NA. Gastrointestinal stromal tumours–an update for histopathologists. Histopathology. 2011;59(5):807–821.
   PubMed Web of Science ®Google Scholar
• Woodall CE, Brock GN, Fan J, et al. An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system. Arch Surg. 2009;144(7):670–678.
   Google Scholar
• Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)–update of the NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw. 2007;5(Suppl 2):S1–S29.
   PubMedGoogle Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70–83.
   PubMed Web of Science ®Google Scholar
• Huang HY, Li CF, Huang WW, et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery. 2007;141(6):748–756.
   Web of Science ®Google Scholar
• Chok AY, Goh BK, Koh YX, et al. Validation of the MSKCC gastrointestinal stromal tumor nomogram and comparison with other prognostication systems: single-institution experience with 289 patients. Ann Surg Oncol. 2015;22(11):3597–3605.
   Web of Science ®Google Scholar
• ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii21–iii26.
   Google Scholar
• Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)–update of the NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw. 2007;5(Suppl 2):S1–S31.
   PubMedGoogle Scholar
• Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002;33(5):459–465.
   PubMed Web of Science ®Google Scholar
• Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10(11):1045–1052.
   PubMed Web of Science ®Google Scholar
• Rossi S, Miceli R, Messerini L, et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol. 2011;35(11):1646–1656.
   Web of Science ®Google Scholar
• Bischof DA, Kim Y, Behman R, et al. A nomogram to predict disease-free survival after surgical resection of GIST. J Gastrointest Surg. 2014;18(12):2123–2129.
   Web of Science ®Google Scholar
• Schmieder M, Henne-Bruns D, Mayer B, et al. Comparison of different risk classification systems in 558 patients with gastrointestinal stromal tumors after R0-resection. Front Pharmacol. 2016;7:504.
   PubMed Web of Science ®Google Scholar
• Belfiori G, Sartelli M, Cardinali L, et al. Risk stratification systems for surgically treated localized primary gastrointestinal stromal tumors (GIST). Review of literature and comparison of the three prognostic criteria: MSKCC Nomogram, NIH-Fletcher and AFIP-Miettinen. Ann Ital Chir. 2015;86(3):219–227.
   Web of Science ®Google Scholar
• Doyle LA, Hornick JL. Gastrointestinal stromal tumours: from KIT to succinate dehydrogenase. Histopathology. 2014;64(1):53–67.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol. 2006;30(1):90–96.
   Web of Science ®Google Scholar
• Zhou C, Duan X, Zhang X, Hu H, Wang D, Shen J. Predictive features of CT for risk stratifications in patients with primary gastrointestinal stromal tumour. Eur Radiol. 2016;26(9):3086–3093.
   Web of Science ®Google Scholar
• Miyake KK, Nakamoto Y, Mikami Y, et al. The predictive value of preoperative 18F-fluorodeoxyglucose PET for postoperative recurrence in patients with localized primary gastrointestinal stromal tumour. Eur Radiol. 2016;26(12):4664–4674.
   Web of Science ®Google Scholar
• Tokumoto N, Tanabe K, Misumi T, Fujikuni N, Suzuki T, Ohdan H. The usefulness of preoperative 18FDG positron-emission tomography and computed tomography for predicting the malignant potential of gastrointestinal stromal tumors. Dig Surg. 2014;31(2):79–86.
   Web of Science ®Google Scholar
• Bertucci F, Finetti P, Mamessier E, et al. PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology. 2015;4(5):e1002729.
   PubMed Web of Science ®Google Scholar
• Suehara Y, Kondo T, Seki K, et al. Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res. 2008;14(6):1707–1717.
   PubMed Web of Science ®Google Scholar
• Orita H. Pfetin as a risk factor of recurrence in gastrointestinal stromal tumors. BioMed Res Int. 2014;651935.
   Web of Science ®Google Scholar
• Huang KK. SETD2 histone modifier loss in aggressive GI stromal tumours. Gut. 2016;65:1960–1972.
   Web of Science ®Google Scholar
• Wang CJ, Zhang ZZ, Xu J, et al. SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis. World J Gastroenterol. 2015;21(27):8398–8407.
   Web of Science ®Google Scholar
• Gyvyte U. MiRNA profiling of gastrointestinal stromal tumors by next-generation sequencing. Oncotarget. 2017;8:37225–37238.
   Google Scholar
• Li CF, Chuang IC, Liu TT, et al. Transcriptomic reappraisal identifies MGLL overexpression as an unfavorable prognosticator in primary gastrointestinal stromal tumors. Oncotarget. 2016;7(31):49986–49997.
   Google Scholar
• Wozniak A, Rutkowski P, Schoffski P, et al. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a European multicenter analysis based on ConticaGIST. Clin Cancer Res. 2014;20(23):6105–6116.
   PubMed Web of Science ®Google Scholar
• Rossi S, Gasparotto D, Miceli R, et al. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study. Am J Surg Pathol. 2015;39(7):922–930.
   PubMed Web of Science ®Google Scholar
• Alkhasawneh A, Reith JD, Toro TZ, et al. Interobserver variability of mitotic index and utility of PHH3 for risk stratification in gastrointestinal stromal tumors. Am J Clin Pathol. 2015;143(3):385–392.
   Web of Science ®Google Scholar
• Rizzo FM, Palmirotta R, Marzullo A, et al. Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations. BMC Cancer. 2016;16:87.
   Web of Science ®Google Scholar
• Zhang Y, Gu ML, Zhou XX, Ma H, Yao HP, Ji F. Altered expression of ETV1 and its contribution to tumorigenic phenotypes in gastrointestinal stromal tumors. Oncol Rep. 2014;32(3):927–934.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hu W, Chen P, et al. Ki67 is a biological marker of malignant risk of gastrointestinal stromal tumors: a systematic review and meta-analysis. Medicine. 2017;96(34):34.
   Web of Science ®Google Scholar
• Stotz M, Liegl-Atzwanger B, Posch F, et al. Blood-based biomarkers are associated with disease recurrence and survival in gastrointestinal stroma tumor patients after surgical resection. PLoS One. 2016;11(7):e0159448.
   Web of Science ®Google Scholar
• Xue A, Gao X, Fang Y, et al. Incorporation of NLR into NIH stratification system increases predictive accuracy for surgically resected gastrointestinal stromal tumors. Acta Biochim Biophys Sin. 2017;49(2):179–185.
   Google Scholar
• Hsiao CY, Yang CY, Lai IR, Chen CN, Lin MT. Laparoscopic resection for large gastric gastrointestinal stromal tumor (GIST): intermediate follow-up results. Surg Endosc. 2015;29(4):868–873.
   Web of Science ®Google Scholar
• Lin J, Huang C, Zheng C, et al. Laparoscopic versus open gastric resection for larger than 5cm primary gastric gastrointestinal stromal tumors (GIST): a size-matched comparison. Surg Endosc. 2014;28(9):2577–2583.
   Web of Science ®Google Scholar
• Piessen G, Lefèvre JH, Cabau M, et al. Laparoscopic versus open surgery for gastric gastrointestinal stromal tumors: what is the impact on postoperative outcome and oncologic results? Ann Surg. 2015;262(5):831–839.
   Web of Science ®Google Scholar
• Joensuu H, Eriksson M, Hall KS, et al. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer. 2014;120(15):2325–2333.
   PubMed Web of Science ®Google Scholar
• Bischof DA, Dodson R, Jimenez MC, et al. Adherence to guidelines for adjuvant imatinib therapy for GIST: a multi-institutional analysis. J Gastrointest Surg. 2015;19(6):1022–1028.
   Web of Science ®Google Scholar
• Guérin A, Sasane M, Keir CH, et al. Physician underestimation of the risk of gastrointestinal stromal tumor recurrence after resection. JAMA Oncol. 2015;1(6):797–805.
   Web of Science ®Google Scholar
• Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097–1104.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265–1272.
   PubMed Web of Science ®Google Scholar
• Trent JC, Subramanian MP. Managing GIST in the imatinib era: optimization of adjuvant therapy. Expert Rev Anticancer Ther. 2014;14(12):1445–1459.
   PubMed Web of Science ®Google Scholar
• Lin JX, Chen QF, Zheng CH, et al. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up. J Cancer Res Clin Oncol. 2017;143(4):727–734.
   Web of Science ®Google Scholar
• Casali PG, Le Cesne A, Poveda Velasco A, et al. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol. 2015;33(36):4276–4283.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial. JAMA Oncol. 2017;3(5):602–609.
   PubMed Web of Science ®Google Scholar
• Agaimy A, Wünsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. 2007;31(1):113–120.
   PubMed Web of Science ®Google Scholar
• Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol. 2006;37(12):1527–1535.
   PubMed Web of Science ®Google Scholar
• Rossi S, Gasparotto D, Toffolatti L, et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34(10):1480–1491.
   Web of Science ®Google Scholar
• Coe TM, Fero KE, Fanta PT, et al. Population-based epidemiology and mortality of small malignant gastrointestinal stromal tumors in the USA. J Gastrointest Surg. 2016;20(6):1132–1140.
   PubMed Web of Science ®Google Scholar
• Nishida T, Hirota S, Yanagisawa A, et al. Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol. 2008;13(5):416–430.
   PubMed Web of Science ®Google Scholar
• Nishida T, Goto O, Raut CP, Yahagi N. Diagnostic and treatment strategy for small gastrointestinal stromal tumors. Cancer. 2016;122(20):3110–3118.
   PubMed Web of Science ®Google Scholar
• Palazzo L, Landi B, Cellier C, Cuillerier E, Roseau G, Barbier JP. Endosonographic features predictive of benign and malignant gastrointestinal stromal cell tumours. Gut. 2000;46(1):88–92.
   Web of Science ®Google Scholar
• Chak A, Canto MI, Rösch T, et al. Endosonographic differentiation of benign and malignant stromal cell tumors. Gastrointest Endosc. 1997;45(6):468–473.
   Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8(Suppl 2): S1–S10.
   PubMed Web of Science ®Google Scholar
• Agaimy A. Gastrointestinal stromal tumor (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. Int J Clin Exp Pathol. 2010;3(5):461–471.
   PubMed Web of Science ®Google Scholar